

# Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

NCT06435858

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Cantonal Hospital Graubünden
Enrollment	40 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Patients 18-75 years old with ADPKD, defined according to international diagnostic and classification criteria<sup>14</sup>, treated at Cantonal Hospital Graubünden (KSGR) and the University Hospital Zürich (USZ) independent of baseline treatment with the vasopressin receptor antagonist Tolvaptan
- Informed consent as documented by signature

### Exclusion (15)

- renal replacement therapy or kidney allograft recipient
- chronic kidney disease CKD KDIGO Stage G4 (eGFR under 30ml/min/1.73m<sup>2</sup>)
- patients younger 18 years of age
- Diabetes mellitus type 1
- recurrent urinary tract infections (UTI) defined as more than 3 infections requiring antibiotic treatment or over 1 requiring hospitalization/year.

... and 10 more (see full listing online)

## Locations (2 total)

---

University Hospital Zurich, Division of Nephrology, Zurich, Canton of Zurich, Switzerland  
Cantonal Hospital Graubünden, Chur, Kanton Graubünden, Switzerland